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Abstract
The aim of the research was to discuss a rare case of synchronous malignant peritoneal mesothelioma of the biphasic his-
tological type and neuroendocrine tumor (NET) of the rectum without history of asbestos exposure and to analyze the outcomes of 
the performed treatment.
Materials and methods. The 48-year-old patient with synchronous malignant peritoneal mesothelioma of the biphasic histo-
logical type and neuroendocrine tumor (NET) of the rectum was analyzed for oncological and clinical outcomes.
Case presentation. During 2 years since manifestation of the disease the patient underwent 3 cytoreductive surgeries (CRS): 
removal of the tumor of the sigmoid mesentery, resection of the rectosigmoid junction completeness of cytoreduction (CC) 0 (2017), 
omentectomy and partial parietal peritonectomy CC-0 (2017), atypical resection of S2, S4, S5 liver, the removal of the abdominal tu-
mor with left-sided en-block hemicolectomy, partial parietal peritonectomy, argon-plasma coagulation of tumor foci on the mesentery 
of the small intestine CC-2 (2018) and Transanal Minimally Invasive Surgery-removal of neuroendocrine rectal tumor (2017). The 
patient underwent hyperthermic intraperitoneal chemotherapy (HIPEC) twice (during 2nd and 3rd CRS). Different regimens of HIPEC 
were performed: cisplatin + doxorubicin (2017) and metamycin C (2018). The patient received 4 courses of adjuvant chemotherapy 
with cisplatin plus pemetrexed in 2017 and 3 courses of the chemotherapy with gemcitabine and carboplatin plus bevacizumab in 2018. 
Results. The patient survived 21 months after the detection of malignant peritoneal mesothelioma in 2017 and died 4 months 
after the last cytoreductive surgery from the progression of the disease.
Conclusions. Histological subtype of MPMP remains important factor in the prognosis of the disease even on the early 
stages though patient had received the most aggressive variant of special treatment. Minimally invasive treatment tactics of NET 
demonstrated clinical effectiveness. 
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Since the 1990s, the techniques for cancer diagnostics and treatment have greatly improved 
worldwide, which have increased the survival period of cancer patients. The prolonged overall 
survival of cancer patients also led to an increase in the incidence of multiple primary malignant 
tumors (two or more histologically distinct malignant tumors that appeared not due to recurrence, 
metastasis or local spread in the same individual). The first report about multiple primary malig-
nant neoplasms in a single patient was published at the end of the 19th century [1]. 
Since then, several papers worldwide have addressed this issue and the prevalence of multi-
ple primary malignant neoplasms reported varies from 0.734 % to 11.7 % [2]. Multiple neoplasms 
could be defined by when they occur as synchronous and metachronous. The co-existence of ma-
lignant peritoneal mesothelioma and neuroendocrine tumor of the rectum is a rare entity. 
Malignant mesothelioma is a rare disease that develops from multipotent mesothelial cells 
of serosal surfaces comprising the pleura, peritoneum, pericardium and tunica vaginalis testis. 
The incidence of diffuse malignant peritoneal mesothelioma (MPMP) reaches 7–30 % of all 
cases [3]. The highest rates are reported in the UK, Australia, and New Zealand. An estimated 
annual incidence of MPM is 2500 cases worldwide [4]. Neuroendocrine tumors originate from 
neuro endocrine cells of endodermal origin, spreading along the gastrointestinal tract. Prevalence 
of neuroendocrine tumor is around 35 cases per 100,000 including all types [5].
Patients with neuroendocrine tumors (NET) of the colon and rectum have a high risk of 
developing metachronous non-carcinoid malignant tumors including malignant mesothelioma with 
a frequency of 25–46 % [6]. Multiple tumors in these cases have a higher potential for malignancy, 
therefore, patients have progression of the disease.
NETs of rectal origin almost never present with the traditional «carcinoid syndrome» symp-
toms characterized by episodic cutaneous flushing and diarrhea [7]. They are often asymptomatic, 
but approximately 50 % can present with rectal bleeding, changes in bowel habits, unexplained 
weight loss, or pain.
In most cases, the clinical presentation of MPM is also asymptomatic. There are no pathog-
nomonic symptoms at initial stages. According to a multicentre cohort study the most frequent 
symptoms/signs were ascites (77 %), abdominal pain (69 %), asthenia (43 %), weight loss (32 %), 
abdominal swelling (30 %) and loss of the appetite (30 %) [3]. Due to the nonspecific nature and 
late manifestation of these symptoms, the decease is often diagnosed at the advanced stages. The 
median time from clinical manifestation to the diagnosis is about 4 months [8]. 
Current guidelines suggest endoscopic resection of rectal NETs ≤10 mm as a safe thera-
peutic option because of their low risk of metastasis [7].
MPM is a life-threatening malignancy that, with no treatment, has a median overall survi-
val of 8.4 months [9]. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemothera-
py (HIPEC) has become the consensus standard first-line therapy for MPM [3]. The median overall 
survival after CRS + HIPEC ranged from 15 to 92 months [3, 4, 9]. This wide range apparently reflects 
various surgeons experience, different status of patients and no standardized technique for HIPEC. 
Herein, we report a rare case of synchronous malignant peritoneal mesothelioma and neuro-
endocrine tumor of the rectum without history of asbestos exposure.
The aim of the research was to discuss a case of synchronous malignant peritoneal meso-
thelioma of the biphasic histological type and neuroendocrine tumor (NET) of the rectum without 
history of asbestos exposure and to analyze the outcomes of the performed treatment.
2. Materials and methods
The 48-year-old patient with synchronous malignant peritoneal mesothelioma of the bipha-
sic histological type and neuroendocrine tumor (NET) of the rectum was analyzed for oncological 
and clinical outcomes. Clinical, laboratory and instrumental examination of patient was performed 
according to the recommendations of the Peritoneal Surface Oncology Group International/Rare 
Adult Solid Cancer clinical practice guidelines for diagnosis, treatment and follow-up of peritoneal 
mesothelioma. The tumor was verified using histological and immunohistochemical examinations. 
Cytoreductive surgery, HIPEC, transanal minimal invasive surgery, adjuvant chemotherapy were 




performed. The condition of patient was assessed by analyzing clinical, instrumental and labo-
ratory parameters.
3. Presentation of the case
The research was carried out within the framework of the scientific work of the Department 
of radiation diagnostics, treatment and oncology of the Odessa National Medical University. Com-
pliance with the WMA Declaration of Helsinki – Ethical Principles for Medical Research Involv-
ing Human Subjects, 2013 (minutes of the meeting of the Committee on Bioethics of the Odessa 
National Medical University No. 148A dated June 15, 2019) was determined. Study participant was 
informed and agreed to the processing of his clinical data and to participate in the research process.
Patient V., 48 years old, consulted his family physician in May 2017 with complaints of 
low-grade fever, dry cough and weight loss during the last 2 months. Computed tomography with 
intravenous contrast (CT) of the chest and the abdomen was performed. According to the CT of the 
abdomen, there was a tumor of the sigmoid mesentery with a diameter of up to 7 cm. In July 2017 he 
was admitted to the surgery department of the oncological center. The removal of the tumor of the 
sigmoid mesentery, resection of the rectosigmoid junction was performed. Intraoperative perito-
neal cancer index (PCI) was estimated 3 points. According to the first histological description, the 
tumor was undifferentiated pleiomorphic sarcoma. Immunohistochemical study was performed and 
malignant mesothelioma of the biphasic type was verified. The patient consulted a clinical onco-
logist in August 2017. Due to the stage 1 disease, no special postoperative treatment was indicated.
In August 2017, according to video-colonoscopy with a biopsy, a submucous tumor of the 
mid-ampullar rectum was found, histologically there were revealed the elements of carcinoma. 
Transanal Minimally Invasive Surgery (TAMIS)-removal of a submucous tumor of the mid-am-
pullar rectum was performed. Histologically and immunohistochemicaly neuroendocrine carci-
noma pT1N0M0G1, pSt.I grade 1 malignancy (atypical carcinoid) was verified.
In September 2017, a screening CT of the chest and the abdomen was performed. CT signs 
of peritoneal carcinomatosis were described. The serum levels of the tumor markers (carcinoem-
bryonic antigen (CEA) and carbohydrate antigen 125 (CA125)) were not elevated.
Сonsidering the CT signs of peritoneal mesothelioma recurrence the patient was admitted to the 
oncological center. Laparoscopic staging and the biopsy of the parietal peritoneum were performed. 
PCI was estimated 4 points. Cytoreductive surgery and HIPEC were recommended to perform. 
In November 2017, patient V. was admitted to the University Clinics of Odessa National Medi-
cal University. Intraoperative PCI was estimated 5 points. The macroscopically complete cytore-
ductive (CC-0) was achieved, which included omentectomy and partial parietal peritonectomy. 
HIPEC with cisplatin 100 mg, doxorubicin 30 mg was performed using the «closed abdomen» tech-
nique (41 °C, 90′). According to the results of histological examination, malignant mesothelioma of the 
biphasic type was verified. The patient was discharged 7 days after CRS + HIPEC in a stable condition.
During the next 3 months, the patient received 4 courses of adjuvant chemotherapy with 
cisplatin plus pemetrexed (PC). 
According to the screening CT of the chest, abdomen and pelvis in February 2018, a recurrent 
tumor was detected in the area of the left colic flexure. The patient refused the surgical treatment. 
From February to May 2018 he received 3 courses of the chemotherapy with gemcitabine 
and carboplatin (GC) plus bevacizumab.
According to the control CT of the chest, abdomen and pelvis in May and August 2018, the 
enlargement of the tumor size up to 8 cm. 
Since September 2018 the patient had concerned on constant fever, pain in the left hypochon-
drium and decrease in body weight. According to the blood test, there was a decrease in the level of 
hemoglobin. In September the CT imaging confirmed multiple nodular tumors of the liver suspected 
to be metastatic (CT of the chest, abdomen, retroperitoneal space and pelvis 09/20/2018 – Disease 
progression. Tumors S2, S4, S5, S8 of the liver up to 1 cm in diameter, probably metastatic are de-
termined. Partially adhering to the splenic angle of the colon, partly to the abdominal wall, a multi-
cameral extraorganic cystic and solid tumor of irregular shape 103×41×67 mm in size is determined). 
According to the data of control video-colonoscopy, no signs of tumor growth were revealed.




In October 2018 percutaneous ultrasound guided liver biopsy was performed. According 
to the results of the histological and immunohistochemical examination, the material is domi-
nated by liver tissue with a focus of malignant tumor: carcinoma with loss of receptor status af-
ter chemotherapy. Taking into account the presence of intractable pain, hyperthermic syndrome, 
sub-compensated bowel obstruction, no positive effect of the systemic chemotherapy, CRS and 
HIPEC was recommended.
In November 2018 he was admitted to the University Clinics of Odessa National Medical 
University for further examination and treatment. At the time of hospitalization, he complained 
about constant pain in the left hypochondriac and left lateral region, which aggravated during 
inspiration and cough; febrile fever, night sweats, dry cough at the height of fever, general weak-
ness, hyporexia, rapid breathing, weight loss up to 10 kg in the last 2 months, constipation, hard 
stools, dizziness, shortness of breath, palpitations. Taking paracetamol, ketorolac was without 
positive effect. 
Intraoperative PCI was estimated 21 points. During the revision of the abdomen metastatic 
lesion of the liver, tumor invasion of the splenic flexure of the colon, peritoneal carcinomatosis of 
the parietal and visceral peritoneum were verified. Suboptimal cytoreductive surgery (CC-2) was 
performed. The extent of the surgery was laparotomy, atypical resection of S2, S4, S5 liver, the 
removal of the abdominal tumor with left-sided en-block hemicolectomy, partial parietal peritonec-
tomy, argon-plasma coagulation of tumor foci on the small intestinal mesentery. Intra-abdomi-
nal hyperthermic chemotherapy with metamycin C was performed using the «closed abdomen» 
technique. The surgery was sub-optimal due to the large extent of the disease and unresectable 
liver metastasis. Intraoperative transfusion of isogroup erythrocyte mass of 600 ml was performed, 
transferred without post-transfusion reactions, complications.
The patient was discharged on the 14th postoperative day in a stable condition, the para-
neoplastic syndrome was arrested.
Further adjuvant palliative polychemotherapy was not given because the patient refused 
additional therapy.
Based on CT screening data and clinically, disease progression was observed in February 2019. 
The patient survived 21 months after the detection of malignant peritoneal mesothelioma in 2017 
and died 4 months after the last cytoreductive surgery from the progression of the disease. 
4. Result and discussion
Based on literature data, rectal NETs compose 1–2 % of all rectal tumors, and generally 
demonstrate a benign clinical profile [7]. After minimally invasive tumor resection, patient V. did 
not receive progression or recurrence of rectal neuroendocrine carcinoma according to video-colo-
noscopy and CT. In this case, the chosen treatment tactics has shown its clinical effectiveness.
According to the review of Kim J. et al. Without treatment, patients with MPMP have a me-
dian survival time of under 5 months to a year after diagnosis [8]. 
For MPMP, the histological subtype has a decisive influence on the life expectancy of pa-
tients, regardless of the specific treatment performed. In the research of Amin et al., for epithe-
lioid histological type the median survival reaches 18 months (95 % CI: 17–21) as compared to 
10 months for biphasic (95 % CI: 9–13) and 7 months for sarcomatoid subtype (95 %CI: 6–11) [10]. 
The research included patients, who received surgery alone, surgery combined with chemotherapy 
and best supportive care. Also, it has been suggested that female patients with mesothelioma have 
a better life expectancy as compared to male patients.
Therefore, it is important to confirm MPMP and to define its histological subtype before 
consider CRS/HIPEC. Patients with the sarcomatoid variant of MPMP are not candidates for CRS; 
however, epithelioid and highly selected biphasic cases are. 
According to the Kim J. et al. investigation, patients with biphasic subtype do not have the 
same survival benefit from CRS+HIPEC when compared to those with epithelioid subtype. In these 
patients, the decision for CRS-HIPEC or systemic chemotherapy is more debatable [8].
In our clinical case, patient received benefit in overall survival compared to the data of the 
literature (21 vs 10 months). The patient had received HIPEC twice (in 2017 with cisplatin + doxo-




rubicin and nearly 12 months later with metamycin C). Both of these chemoperfusion regimens 
are currently used for treatment of MPMP [11]. 
The most effective cytostatic therapy for MPMP is considered pemetrexed, with either cis-
platin or carboplatin. Failure to obtain disease control is an indication for another regimen such 
as cisplatin with irinotecan, gemcitabine with cisplatin/carboplatin [12]. Another alternative for 
second-line systemic treatment is the use of a molecular agent, such as bevacizumab [12]. All of the 
second-line therapies are still under investigation. 
Study limitations. The limitations were the lack of ability to generalize, no possibility to 
establish cause-effect relationship, danger of over-interpretation, publication bias and the retro-
spective design of the study.
Рrospects for further research. The research should be continued in a larger number of 
patients to form the effective approaches to the treatment and diagnosis of malignant peritoneal 
mesothelioma. 
5. Conclusions 
Both MPMP and NET of the rectum could be diagnosed on the late stages due to their 
asymptomatic clinics. MPMP could be misdiagnosed as recurrence or metastasis of another ma-
lignancy in patient with synchronous or metachronous malignancies, which may result in inappro-
priate treatment. This inevitably could have negative influence on the patient’s prognosis.
Malignant peritoneal mesothelioma creates a challenge for oncologists in terms of rare silent 
disease, diagnosis, complex treatment and poor prognosis. MPMР continues to have a poor progno-
sis because of the limited therapeutic options. Because of the rarity of disease, it is difficult to pro-
vide patient participation in prospective clinical trials with the purpose of treatment standardization. 
Histological subtype of the tumor remains an important factor in the prognosis of the disease even 
on the early stages though patient had received the most aggressive variant of special treatment. 
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